Press release
Bevacizumab Biosimilars Market Forecasted to Reach USD 9.8 Billion by 2034, Key Players: Amgen & Pfizer
Bevacizumab Biosimilars
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72673
Market Overview
• Market Size 2024: USD 2.7 billion
• Forecast 2034: USD 9.8 billion
• CAGR (2024-2034): 13.5%
Key Highlights:
• Patent expiries of Avastin have opened lucrative opportunities for biosimilar manufacturers.
• Increasing cancer incidence worldwide, particularly colorectal and lung cancers, drives demand.
• Governments and payers are encouraging biosimilar adoption to reduce treatment costs.
• Strategic partnerships between biotech firms and pharmaceutical companies are expediting commercialization.
Challenges include regulatory complexities, physician reluctance in some regions, and high development costs. Yet, the overall trajectory remains strongly positive.
Market Segmentation
By Product Type
• Recombinant Humanized Monoclonal Antibodies (Bevacizumab)
• Combination Formulations
By Indication
• Colorectal Cancer
• Non-small Cell Lung Cancer (NSCLC)
• Renal Cell Carcinoma
• Ovarian Cancer
• Glioblastoma
• Others (including cervical and hepatocellular cancers)
By End User
• Hospitals
• Specialty Clinics
• Research & Academic Institutes
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Segmentation Summary:
Colorectal cancer remains the leading application segment due to its high global prevalence. NSCLC is the fastest-growing segment, reflecting the increasing burden of lung cancer worldwide. Hospitals dominate as the primary end users, while online pharmacies are expected to grow rapidly with rising digital healthcare adoption.
Explore Full Report here: https://exactitudeconsultancy.com/reports/72673/bevacizumab-biosimilars-market
Regional Analysis
North America
• Largest market in 2024, driven by strong biosimilar uptake and favorable reimbursement policies.
• The U.S. leads, with increasing FDA approvals and strong presence of both originator and biosimilar manufacturers.
Europe
• Accounts for nearly 30% of the market.
• EMA's supportive regulatory framework and cost-containment policies are accelerating biosimilar adoption.
• Germany, France, and the UK are leading markets.
Asia-Pacific
• Fastest-growing region, projected CAGR of over 15%.
• India, China, and South Korea are key hubs due to growing cancer burden and biosimilar manufacturing capacity.
• Increasing healthcare expenditure and government initiatives boost adoption.
Middle East & Africa
• Early-stage adoption, but demand is rising as oncology treatment access expands.
• Partnerships with global pharma companies support availability.
Latin America
• Brazil and Mexico are primary contributors, supported by expanding oncology care infrastructure.
• Cost advantages of biosimilars over branded biologics drive growth.
Regional Summary:
North America and Europe dominate current adoption, but Asia-Pacific will emerge as the fastest-growing market by 2034, fueled by local manufacturing capabilities, government support, and high unmet medical needs.
Market Dynamics
Growth Drivers
• Patent Expiry of Avastin: Creates significant opportunities for biosimilar entrants.
• Rising Cancer Incidence: Global burden of colorectal, lung, and ovarian cancers fuels demand.
• Cost-effectiveness: Biosimilars offer affordable alternatives, increasing patient accessibility.
• Regulatory Support: Streamlined approval pathways in Europe, U.S., and Asia are encouraging innovation.
Key Challenges
• Physician Reluctance: Some healthcare professionals remain cautious in prescribing biosimilars.
• High Development Costs: Manufacturing biologics and meeting regulatory requirements is capital intensive.
• Market Competition: Intense competition among biosimilar developers can limit pricing power.
Latest Trends
• Combination Therapies: Biosimilars being tested with other oncology treatments to enhance outcomes.
• Strategic Partnerships: Co-development and licensing deals are becoming common to reduce risks.
• Oncology Pipeline Expansion: Focus shifting toward biosimilars for other monoclonal antibodies in oncology.
• Digital Health Integration: E-commerce and online pharmacies enabling wider access to biosimilars.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72673
Competitive Landscape
Key Players
• Amgen Inc.
• Pfizer Inc.
• Biocon Biologics Ltd.
• Celltrion Healthcare
• Samsung Bioepis
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V. (Viatris)
• Genentech (Roche)
• Dr. Reddy's Laboratories
• Sandoz (Novartis Division)
• BeiGene
• Innovent Biologics
• STADA Arzneimittel AG
• Apotex Inc.
• Amneal Pharmaceuticals
Competitive Summary:
The Bevacizumab biosimilars market is highly competitive, with several global and regional players vying for market share. Partnerships and co-marketing agreements are common strategies to accelerate commercialization. Companies like Amgen, Pfizer, and Biocon have already launched biosimilars in multiple markets, while Asian firms like Celltrion and Samsung Bioepis are expanding aggressively. Roche continues to defend its Avastin franchise but faces declining revenue share due to biosimilar uptake.
Conclusion
The Bevacizumab Biosimilars Market is projected to grow from USD 2.7 billion in 2024 to USD 9.8 billion by 2034, at a strong CAGR of 13.5%. With rising cancer cases and increasing focus on cost containment, biosimilars offer a sustainable solution for global oncology care.
North America and Europe currently lead adoption, but Asia-Pacific will drive the next phase of growth, reshaping the competitive landscape.
Advances in manufacturing technologies, combination therapies, and regulatory approvals will accelerate market penetration, while collaborations between pharma giants and biotech firms will enhance global reach.
For healthcare providers, patients, and investors, Bevacizumab biosimilars represent a critical frontier in making life-saving cancer treatments more accessible and affordable worldwide.
This report is also available in the following languages : Japanese (ベバシズマブバイオシミラー市場), Korean (베바시주맙 바이오시밀러 시장), Chinese (贝伐珠单抗生物类似药市场), French (Marché des biosimilaires du bevacizumab), German (Markt für Bevacizumab-Biosimilars), and Italian (Mercato dei biosimilari di Bevacizumab), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72673/bevacizumab-biosimilars-market#request-a-sample
Our More Reports:
Viral Vaccine Cell Culture Media Market
https://exactitudeconsultancy.com/reports/73525/viral-vaccine-cell-culture-media-market
NGS Kits Market
https://exactitudeconsultancy.com/reports/73526/ngs-kits-market
Single Use Sensors Market
https://exactitudeconsultancy.com/reports/73527/single-use-sensors-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bevacizumab Biosimilars Market Forecasted to Reach USD 9.8 Billion by 2034, Key Players: Amgen & Pfizer here
News-ID: 4204263 • Views: …
More Releases from Exactitude Consultancy
Self-amplified tumor-targeting therapy using vascular-disrupting chemicals
Introduction
Vascular Disrupting Agents (VDAs) represent an innovative class of oncology drugs designed to selectively damage the established blood vessels within tumors, leading to rapid ischemia and cancer cell death. Unlike anti-angiogenic agents that inhibit the formation of new blood vessels, VDAs target existing tumor vasculature, offering a complementary approach to cancer treatment.
With cancer incidence rising worldwide and limitations of conventional chemotherapy and radiation persisting, VDAs are gaining attention as part…
Biospecimen Procurement Market Forecasted to Reach USD 120.8 Billion by 2034, Ke …
The rise of precision medicine, biomarker discovery, and advanced diagnostics has made biospecimen procurement a cornerstone of modern healthcare and life sciences research. Biospecimens-including blood, tissue, plasma, urine, and other human-derived samples-are critical for drug discovery, translational research, and clinical trials. Pharmaceutical companies, academic institutions, and diagnostic firms rely on high-quality biospecimens to accelerate product development and regulatory approvals.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72675
With growing global…
TIL Therapy Market to Reach USD 2.14 Billion by 2034, Growing at 17.8% CAGR
Introduction
Tumor-Infiltrating Lymphocyte (TIL) therapy represents one of the most promising advancements in cancer immunotherapy. By harnessing and expanding a patient's own immune cells to fight tumors, TIL therapy has demonstrated strong clinical potential in treating solid tumors such as melanoma, lung cancer, and cervical cancer.
Unlike CAR-T therapies, which have shown greater success in hematological malignancies, TIL therapy is uniquely positioned for solid tumor treatment-a segment that accounts for the majority…
Market for clinical trial design is expected to grow to USD 32.4 billion by 2034 …
Clinical trials form the backbone of modern drug and device development. However, the rising complexity of diseases, patient diversity, and the demand for faster, cost-efficient approvals have transformed the way trials are designed. The clinical trial design market is witnessing a paradigm shift from traditional randomized controlled trials to more adaptive, decentralized, and patient-centric designs. These innovative models not only reduce time and cost but also improve trial efficiency and…
More Releases for Bevacizumab
Key Trends Reshaping the Bevacizumab Biosimilars Market: Advancing Product Innov …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Bevacizumab Biosimilars Market Size Growth Forecast: What to Expect by 2025?
Over the past few years, the bevacizumab biosimilars market has been experiencing robust growth. The market, which was valued at $1.53 billion in 2024, will surge to $1.64 billion in 2025, reflecting a compound annual growth rate (CAGR)…
Global Bevacizumab Biosimilars Market Outlook 2025-2034: Trends, Innovations, An …
The Bevacizumab Biosimilars Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Bevacizumab Biosimilars Market Size During the Forecast Period?
There has been a robust expansion in the market size of bevacizumab biosimilars in the past few years. The market is projected to…
Key Trend Reshaping the Bevacizumab Biosimilars Market in 2025: Advancing Produc …
What combination of drivers is leading to accelerated growth in the bevacizumab biosimilars market?
An increasing number of cancer cases is anticipated to fuel the expansion of the bevacizumab biosimilar market in the future. The term cancer incidence refers to the tally of new cancer diagnoses within a certain demographic over a specified timeframe. Bevacizumab is a biologic agent that hinders tumor angiogenesis, resulting in the potential reduction and inhibition of…
Rising Cancer Prevalence Drives Growth Of The Avastin (Bevacizumab) Market: Majo …
What Are the Market Size and Growth Forecast for the Avastin (Bevacizumab) Market?
In recent times, the market size for avastin (bevacizumab) has seen significant growth. A projection predicts that the value will increase from $7,251.35 million in 2024 to $7,819.19 million in 2025, growing at a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth during the historic period include the approval from regulatory bodies, an increase…
Rising Cancer Prevalence Drives Growth Of The Avastin (Bevacizumab) Market: Majo …
What Are the Market Size and Growth Forecast for the Avastin (Bevacizumab) Market?
In recent times, the market size for avastin (bevacizumab) has seen significant growth. A projection predicts that the value will increase from $7,251.35 million in 2024 to $7,819.19 million in 2025, growing at a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth during the historic period include the approval from regulatory bodies, an increase…
2020-2025: Bevacizumab Biosimilar Market Report Covers Growing Strategies Used B …
Business Industry Reports Research has recently announced a report on Global Bevacizumab Biosimilar Market based on the Healthcare Industry. The Bevacizumab Biosimilar Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2025.
Global Bevacizumab Biosimilar Market overview:
A biosimilar is a biologic medical product (also known as biologic) highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are…
